Kamada (NASDAQ:KMDA) Stock Price Passes Below 200-Day Moving Average – What’s Next?

Shares of Kamada Ltd. (NASDAQ:KMDA) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.38 and traded as low as $6.15. Kamada shares last traded at $6.28, with a volume of 82,005 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research report on Thursday, March 6th. Benchmark started coverage on Kamada in a research report on Friday, March 21st. They set a “buy” rating and a $15.00 price objective for the company. Finally, StockNews.com cut Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 25th.

Kamada Trading Up 3.5 %

The company’s 50 day simple moving average is $6.95 and its 200 day simple moving average is $6.38. The stock has a market capitalization of $360.97 million, a PE ratio of 22.43, a PEG ratio of 0.97 and a beta of 1.07.

Kamada Dividend Announcement

The firm also recently announced a — dividend, which was paid on Monday, April 7th. Investors of record on Monday, March 17th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Monday, March 17th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KMDA. Geode Capital Management LLC increased its position in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 1,549 shares during the last quarter. Aristides Capital LLC boosted its holdings in Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the last quarter. NewEdge Advisors LLC grew its position in Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares during the period. JPMorgan Chase & Co. acquired a new stake in Kamada during the fourth quarter worth about $67,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Kamada in the 3rd quarter worth about $77,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.